Does Aetna (CVS Health) Cover Praluent (Alirocumab)?

What Aetna's Default Coverage Policy Says About Praluent

Aetna (CVS Health) covers Praluent on most commercial PPO and HMO plans, but coverage is conditional. The plan places alirocumab on a specialty formulary tier (typically Tier 4 or Tier 5) and requires prior authorization before dispensing. Aetna's Clinical Policy Bulletins (CPBs) align with the ACC/AHA cholesterol guideline framework, which designates PCSK9 inhibitors as second-line agents after statin and ezetimibe therapy has been optimized [1]. That alignment means your prescriber must document both a qualifying diagnosis and prior treatment failure or intolerance before Aetna will approve the drug.

The two FDA-approved indications that Aetna recognizes for Praluent are: (1) adults with primary hyperlipidemia, including HeFH, as an adjunct to diet and maximally tolerated statin therapy; and (2) adults with established ASCVD who require additional LDL-C lowering [2]. Aetna's medical necessity standard for the ASCVD indication typically requires an LDL-C of 70 mg/dL or higher despite stable statin therapy, a threshold that mirrors ACC/AHA 2018 Guideline on the Management of Blood Cholesterol recommendations [1].

The plan does not cover Praluent for weight loss, non-cardiovascular lipid conditions, or off-label indications. Any prescription submitted for those purposes will receive an automatic denial.

Prior Authorization Criteria for Praluent on Aetna

Praluent PA is moderate-to-high difficulty on Aetna. Expect to supply all four categories of documentation below.

Diagnosis documentation. The chart must confirm one of the following: (a) HeFH diagnosed by genetic testing or a clinical scoring system such as the Dutch Lipid Clinic Network score of 6 or higher; or (b) established ASCVD defined as prior acute coronary syndrome, history of myocardial infarction, stable or unstable angina, coronary or arterial revascularization, stroke, transient ischemic attack, or symptomatic peripheral arterial disease [1].

Baseline LDL-C. A fasting lipid panel drawn while the patient is already on maximally tolerated statin therapy must show LDL-C at or above the plan's threshold, typically 70 mg/dL for ASCVD patients and 100 mg/dL for HeFH patients without ASCVD. Labs must be dated within 90 days of the PA submission in most Aetna regions [3].

Step therapy documentation. The prescriber must show that the patient has tried at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) at the maximum tolerated dose for at least 3 months, plus ezetimibe 10 mg for at least 3 months, and that LDL-C remains above threshold despite those agents [1]. Statin intolerance requires chart-documented myopathy, myalgia, or hepatotoxicity on two separate statins, with CK or liver enzyme values where available [4].

Prescriber specialty. Aetna often requires that the ordering provider be a cardiologist, lipidologist, or endocrinologist, or that the primary-care prescriber document a referral or comanagement with one of those specialties. This requirement varies by plan contract.

Reauthorization is typically required every 12 months, and Aetna may require repeat LDL-C labs showing a treatment response of at least 50% LDL-C reduction, consistent with expected PCSK9-inhibitor pharmacodynamics [5].

The Clinical Evidence Behind Why Aetna Covers Praluent at All

Aetna's coverage policy exists because the cardiovascular outcomes data for alirocumab is substantial. The ODYSSEY OUTCOMES trial (N=18,924) enrolled patients who had an acute coronary syndrome 1 to 12 months prior and were already on high-intensity or maximum-tolerated statin therapy [6]. At a median follow-up of 2.8 years, alirocumab 75 to 150 mg every 2 weeks reduced the composite of coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, and unstable angina requiring hospitalization by a relative 15% compared with placebo (hazard ratio 0.85 to 95% CI 0.78, 0.93, P<0.001) [6]. Patients in the highest baseline LDL-C quartile (median 99 mg/dL) saw a 24% relative risk reduction [6].

Mean LDL-C fell from 87.5 mg/dL at baseline to 53.3 mg/dL at 4 months in the alirocumab arm, a reduction of approximately 39% on top of statin background therapy [6]. The FDA approved the ASCVD-risk reduction indication for alirocumab in April 2019 based on that data [2].

Earlier, the ODYSSEY FH I and FH II trials (combined N=735) established the HeFH indication. Alirocumab 75 to 150 mg every 2 weeks lowered LDL-C by 48.8% in FH I and 48.7% in FH II versus placebo at week 24, with P<0.0001 in both trials [7]. Those reductions supported the original 2015 FDA approval [2].

The ACC/AHA 2018 cholesterol guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C level remains 70 mg/dL or higher" after maximally tolerated statin and ezetimibe [1]. That language is the clinical foundation for Aetna's PA criteria.

Step Therapy: What Counts as an Adequate Trial

Step therapy is the single most common reason Aetna denies a Praluent PA on first submission. Getting this right the first time saves weeks of delay.

Adequate statin trial means a minimum of 3 consecutive months on atorvastatin 40 mg or 80 mg, or rosuvastatin 20 mg or 40 mg, documented by pharmacy fill records or chart notes. A 30-day trial, or a trial that was stopped due to cost rather than tolerability, generally does not qualify [4]. The SAMSON trial (N=60) confirmed that nocebo effects account for a majority of statin side-effect reports, so Aetna reviewers are trained to look for objective evidence of intolerance such as CK elevation above 10x the upper limit of normal, or documented hepatotoxicity [8].

Ezetimibe 10 mg must be added to the statin regimen, not used as a replacement for it, for at least 3 months. Aetna will also accept documentation that ezetimibe was contraindicated or caused an adverse reaction, though this is uncommon.

If the patient is statin-intolerant, the prescriber should document trials on at least two different statins with objective adverse effects, alternative dosing strategies such as every-other-day dosing of rosuvastatin, and the reason those strategies failed. The ACC/AHA and the National Lipid Association both define statin intolerance as the inability to tolerate two or more statins due to dose-dependent adverse effects [1][4].

Bempedoic acid (Nexletol) has emerged as an additional step-therapy agent. Some Aetna plan contracts now require a bempedoic acid trial for statin-intolerant patients before authorizing a PCSK9 inhibitor. Confirm the specific contract language with Aetna's pharmacy team before submitting the PA [3].

The HealthRX Aetna Praluent PA Readiness Checklist (for prescribers to complete before submission):

1. Confirmed diagnosis code: HeFH (E78.01) or ASCVD (I25.10, I21.x, I63.x, or equivalent).
2. Fasting LDL-C on maximally tolerated statin: dated within 90 days, at or above plan threshold.
3. Statin trial documentation: drug name, dose, duration (minimum 3 months), fill records attached.
4. Ezetimibe trial documentation: 10 mg daily, minimum 3 months, or documented contraindication.
5. Bempedoic acid trial (if statin-intolerant): per specific plan contract requirement.
6. Specialty prescriber or comanagement note from cardiologist/lipidologist.
7. Letter of medical necessity signed by ordering physician.

Submitting all seven elements on the first PA request reduces the average time to approval, because Aetna's pharmacy reviewers have everything they need without sending a deficiency notice [3].

How Aetna Formulary Tiers Affect Your Out-of-Pocket Cost

Praluent sits on Specialty Tier (Tier 4 or Tier 5) on virtually all Aetna commercial formularies. The exact cost-sharing depends on the specific plan design, but specialty copays or coinsurance rates on Aetna plans typically range from $100 to $300 per 30-day supply after deductible, with some plans applying 20 to 33% coinsurance on specialty drugs [3]. For a drug with a list price near $580 per month, 20% coinsurance would mean roughly $116 per fill after deductible.

Aetna Medicare Advantage plans follow CMS Part D formulary rules. In the Part D structure, specialty-tier drugs are subject to the catastrophic coverage threshold under the Inflation Reduction Act, which caps out-of-pocket drug spending at $2,000 per year starting in 2025 [9]. That cap may significantly reduce total annual alirocumab costs for Medicare patients who previously cycled through the coverage gap.

Aetna Medicaid (Medicaid Managed Care) formulary coverage varies by state contract. Some states include PCSK9 inhibitors with prior authorization; others apply more restrictive criteria or do not include them on the preferred drug list at all [3].

Appealing a Praluent Denial from Aetna

Aetna denies Praluent PAs primarily for three reasons: insufficient step-therapy documentation, LDL-C below the plan's threshold, or a prescriber who does not meet the specialty requirement. Each denial letter will cite the specific reason, and the appeal must address that exact issue.

First-level internal appeal. File within 180 days of the denial date. Submit a complete appeal packet that includes: the denial letter, a letter of medical necessity with updated LDL-C labs, full step-therapy documentation (pharmacy records, chart notes for adverse effects), a copy of the ACC/AHA 2018 guideline recommendation [1], and the relevant ODYSSEY OUTCOMES data showing mortality and cardiovascular event reduction [6]. Aetna must issue a decision within 30 days for non-urgent appeals or 72 hours for urgent cases under ERISA and ACA timelines.

Second-level internal appeal or peer-to-peer review. If the first-level appeal is denied, the prescribing physician can request a peer-to-peer call with Aetna's medical director. This call should be handled by the cardiologist or lipidologist, not administrative staff. The physician should reference specific patient risk factors, baseline LDL-C values, ODYSSEY OUTCOMES outcome data for high-risk subgroups [6], and why the clinical evidence supports this specific patient.

External independent review. If both internal levels fail, federal law under the ACA requires that Aetna offer an independent external review by an accredited Independent Review Organization (IRO). The IRO decision is binding on the insurer [10]. External review overturns denials in a meaningful proportion of cases involving specialty drugs when the appeal packet includes current guideline support.

State insurance commissioner complaint. File simultaneously with the external review if the denial appears to violate state mental health parity laws or any state-specific mandated-benefit statute. Some states have enacted laws specifically requiring coverage of PCSK9 inhibitors for high-risk patients [3].

The American College of Cardiology has published guidance noting that "coverage restrictions for PCSK9 inhibitors remain a significant barrier to guideline-directed medical therapy" for very-high-risk ASCVD patients [11]. Citing this directly in an appeal letter contextualizes the denial as potentially inconsistent with accepted cardiology standards of care.

Manufacturer Savings Card and Patient Assistance Programs

Sanofi and Regeneron offer the Praluent My$avings Card for commercially insured patients. Eligible patients with commercial insurance (not Medicare or Medicaid) may pay as little as $0 per month for a 30-day supply, subject to program terms and a monthly benefit cap [12]. The card cannot be used for government-funded insurance plans, including Medicare Part D, Medicaid, TRICARE, or VA coverage, due to federal anti-kickback statute restrictions [12].

To confirm current eligibility and benefit caps, visit the Praluent manufacturer savings page or call 1-888-PRALUENT. Terms change periodically and the savings card does not apply to all plan types.

For patients who are uninsured or underinsured and do not qualify for the savings card, Sanofi offers the Insulins Valyou Savings Program and broader patient assistance through Sanofi Patient Connection at 1-888-847-4877. Patients below 400% of the federal poverty level may qualify for the drug at no cost [12].

The out-of-pocket cost without any assistance is approximately $580 per month at list price, making access to either the savings card or manufacturer assistance financially significant for most patients [3].

LDL-C Targets That Justify Praluent Prescribing

Getting the LDL-C documentation right is as important as the step-therapy records. Aetna's medical necessity thresholds map closely to guideline recommendations, so understanding those targets helps prescribers frame the PA correctly.

For very-high-risk ASCVD patients, the ACC/AHA 2018 guideline recommends an LDL-C target below 70 mg/dL, and adds a PCSK9 inhibitor when LDL-C remains at or above that threshold on maximally tolerated statin plus ezetimibe [1]. The European Society of Cardiology 2019 guideline is even more aggressive, recommending below 55 mg/dL for very-high-risk patients [13]. Aetna typically uses the ACC/AHA 70 mg/dL threshold rather than the ESC target, but citing both in an appeal strengthens the argument.

For HeFH patients without ASCVD, Aetna generally applies a 100 mg/dL threshold for PA approval, consistent with NLA and ACC/AHA guidance for that population [4]. Patients with homozygous FH (HoFH) are a distinct population; alirocumab is not FDA-approved for HoFH, and Aetna does not cover it for that indication through standard PA pathways [2].

Alirocumab at 150 mg every 2 weeks produces LDL-C reductions of approximately 54 to 62% from baseline in trials [5][7]. At 75 mg every 2 weeks, reductions average 44 to 48% [7]. Those magnitudes are pharmacologically sufficient to bring most patients below either the ACC/AHA or ESC target when added to background statin therapy, which is the clinical rationale the prescriber should articulate clearly in the PA letter.

Special Populations and Coverage Nuances

Statin-intolerant patients. Aetna may approve Praluent as monotherapy (without background statin) for documented statin-intolerant patients. The FDA label permits this use [2]. The prescriber must provide a statin intolerance summary citing the specific statins tried, doses, duration, and adverse effects with supporting labs. A published 2022 systematic review in the European Heart Journal found PCSK9 inhibitors effective and well-tolerated in fully statin-intolerant patients, with LDL-C reductions of 51 to 55% as monotherapy [5].

Post-ACS patients in the first year. ODYSSEY OUTCOMES enrolled patients as early as 1 month post-ACS [6]. Aetna may be more willing to approve Praluent within the first 12 months after an acute coronary syndrome if LDL-C remains above 70 mg/dL on maximally tolerated therapy, because this is the period of highest residual risk. Document the ACS date explicitly in the PA request.

Pediatric HeFH. The FDA approved alirocumab for HeFH in pediatric patients age 8 and older in 2023, based on the ODYSSEY PEDS trial [2]. Aetna's coverage policy for pediatric patients is still evolving. Prescribers should contact Aetna's specialty pharmacy team directly for the current pediatric PA criteria, as standard adult CPB criteria do not always apply.

Pregnancy and lactation. Alirocumab is not recommended during pregnancy. The FDA label notes limited human data and potential fetal risk based on animal studies [2]. Aetna will not cover Praluent for pregnant patients under standard criteria, and the clinical indication is absent in this population.

What to Do if Aetna Still Denies After Appeal

If all internal appeals and external review fail, three pathways remain available.

First, contact Aetna's case management team to request a single-case agreement (SCA). An SCA is a one-time authorization that bypasses standard formulary rules. SCAs are granted rarely but are possible when a patient's clinical circumstances are genuinely exceptional and the prescriber can document why no alternative agent is appropriate [3].

Second, explore switching to evolocumab (Repatha), the other approved PCSK9 inhibitor. Aetna may have different formulary placement or PA criteria for evolocumab on specific plan contracts. The clinical outcomes data (FOURIER trial, N=27,564) shows a similar cardiovascular risk profile to alirocumab [14]. If Repatha is on a lower formulary tier or has a simpler PA pathway on the patient's specific Aetna plan, it may be the faster route to initiating PCSK9 inhibitor therapy.

Third, if the patient's LDL-C reduction need is moderate rather than severe, inclisiran (Leqvio), a small interfering RNA agent approved by the FDA in December 2021, offers twice-yearly dosing and comparable LDL-C lowering [15]. Aetna's formulary placement for inclisiran differs by plan, and some plans may have more favorable tiering or PA criteria for this newer agent.